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Abstract
The purpose of this cross-sectional study was to investigate the prevalence and correlates of diabetic peripheral neuropathy
(DPN) in a Saudi population. The study population consisted of 552 diabetic participants with an average age of 53.4 years.
Among this population, 62.7% were male and 94.9% had type 2 diabetes. The average body mass index was 31.1 kg/m
2.
DPN was diagnosed based on a combination of reduced vibration perception measured by neurothesiometer and/or
reduced light touch perception evaluated by the 10-g Semmes-Weinstein monofilament, as well as neurological symptoms.
Information on socio-demographic variables, smoking status, duration of diabetes, and medications was obtained through
interviews by physicians. Body weight, height, waist circumference, blood pressure and clinical markers were assessed
following standard procedures. The prevalence of DPN in this population was 19.9% (95% CI, 16.7%-23.5%). In the
multivariable analyses, longer duration of diabetes [odds ratio (OR) for every 5-year increase, 2.49, 95% CI, 1.75-3.53],
abdominal obesity (OR, 2.53, 95% CI, 1.41-4.55), and higher levels of fasting blood glucose (OR for every 1 mmol/L increase,
1.05, 95% CI, 0.99-1.12), creatinine (OR for every 10 mmol/L increase, 1.07, 95% CI, 0.99-1.14) and white blood cell count (OR
for every 10
6/L increase, 1.08, 95% CI, 1.01-1.16) were associated with higher odds of DPN, while oral hypoglycemic
medication use was associated with a lower odds of DPN (OR, 0.47, 95% CI, 0.26-0.85). In this large Saudi population, several
correlates for DPN, in addition to glycemic control and diabetes duration, were identified, including abdominal obesity,
creatinine and white blood cell count.
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Introduction
As a common complication of diabetes, diabetic peripheral
neuropathy (DPN) is associated with a wide range of clinical
manifestations, and predicts foot ulcer, lower-extremity amputa-
tion and mortality in diabetic patients [1], accounting for a
massive amount of economic burden to healthcare system [2]. In
addition, DPN is one of the most insidious complications of
diabetes. Up to 50% of patients with DPN are asymptomatic but
may already develop insensate foot injury [1]. Therefore, early
recognition of high-risk population is enormously important so
that rigorous modification of risk factors, accompanying foot care,
could be implemented before or at early stage of neuropathic
process, which will prevent the occurrence and improve the
prognosis of DPN. However, according to the latest statement
regarding DPN from the American Diabetes Association (ADA),
other than strict blood glucose control, no prevention and
treatment measures for DPN were recommended due to the lack
of reliable scientific evidence [1]. Furthermore, the Diabetes
Control and Complications Trial found that, even under rigorous
blood glucose control, patients still presented substantially high
cumulative incidence of DPN, suggesting that risk factors apart
from blood glucose level could play an important role in the
development of DPN [3]. Existing evidence suggests duration and
level of hyperglycemia [3,4], dyslipidemia, body mass index (BMI),
smoking, hypertension [5] and height [6] as risk factors for DPN,
but overall evidence is still limited.
Due to the dramatic changes on lifestyle and diet in the past
decades, by 2011, Saudi Arabia (SA) has ranked as the country
with the 7th highest adult diabetes prevalence (24.0%) around the
world [7]. Furthermore, the prevalence of DPN in Middle-Eastern
diabetic populations is relatively high. For example, in Bahrain, a
neighboring country of SA, a DPN prevalence of 36.6% has been
reported in a large diabetic population [8], comparable to that in
U.S. diabetic populations (12% – 50%) [2]. Although the high
prevalence of both diabetes and its complications threatens to
overburden the health care system and create insurmountable
public health challenges in SA, few studies have addressed
potential risk factors of DPN in Saudi populations, which could
be different from those already reported in other populations,
because diabetic population in the Middle East usually have
poorer glycemic control compared to those in developed countries
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in diabetic populations could also contribute to different pattern of
correlates of DPN [10]. Therefore, identifying correlates for DPN,
as potential risk predictors, in order to facilitate DPN management
is of great public health importance in SA [11].
In this present study, we investigated the prevalence and
correlates for DPN among a diabetic population in Western SA.
Methods
From June 2009 to May 2010, we published the invitation to
participate our study in a widely read newspaper in Jeddah
Governance, Saudi Arabia for recruitment of potential partici-
pants. Respondents to our invitation contacted our study staff
through telephone to confirm their first clinical visit. During the
first visit, they were screened by a questionnaire and clinical
examinations based on inclusion and exclusion criteria. The
inclusion criteria were age of 30 years or older and the history of
diabetes of 2 years or longer. The exclusion criterion was presence
of foot ulcer. The final study population was comprised of 552
participants. Compared to a nationally representative sample of
diabetic patients for estimating the prevalence of DPN, our study
population had similar demographic characteristics [12]. The
study was approved by the King Abdulaziz University Hospital
(KAUH) Ethical Committee. Study methods, benefits and adverse
reactions, and objectives of this study were explained to all
participants. Written consent was obtained from every participant.
The diagnosis and type of diabetes mellitus was first self-reported
by participants and then confirmed by physicians using medical
records. A questionnaire was administered in person by a vascular
specialist and a trained nurse to collect information on nationality,
age, smoking status, personal income level, educational attain-
ment, current medication use and duration of diabetes. Nationality
was classified as Saudi and non-Saudi. Smoking status was
classified as ever smoker and never smoker. Personal income level
was categorized as ,3000, 3000–10000 and .10000 Saudi Riyal
(SR)/month (1 USD =3.75 SR). We categorized education
attainment as illiterate, high school, university, and post-graduate.
Duration of diabetes was categorized into 2–5, 5–10, 10–20 and
.20 years.
The participant’s body weight was measured to the nearest of
0.1 kg by an electronic weighing scale (Seca, Birmingham, United
Kingdom). Height was measured without shoes to the nearest of
0.5 cm using a stadiometer (Seca, Birmingham, United Kingdom).
Body mass index (BMI) was calculated as weight (kg) divided by
height (m) squared (kg/m
2). Waist circumference was measured at
the smallest circumference between the rib margin and iliac crest.
The cutoff points of BMI recommended by the World Health
Organization (WHO) were used to define obesity ($30 kg/m
2)
[13]. Abdominal obesity was defined as waist circumference
$102 cm for men and $88 cm for women. All participants’ blood
pressures were measured by an electronic vital signs monitor
(SuresignsVs3, Philips medical system, Andover, MA, USA). Two
consecutive readings of blood pressure were taken in the right arm
of participants in a seated position after 5 minutes of rest. The
mean of the 2 measures was used for analysis. In this study,
hypertension was defined as systolic blood pressure (SBP)
$140 mmHg and/or diastolic blood pressure (DBP) $90 mmHg
according to the Seventh Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood
Pressure guidelines [14], and/or using the blood-pressure-lowering
drugs. In our study, the diagnosis of DPN was based on a
combination of both decreased sensation (reduced vibration
perception and/or reduced light touch perception in either foot)
and neuropathic sensory symptoms (loss of pinprick sensations,
tingling, and deformed foot). Vibration perception was assessed
over bony prominences on dorsal aspect of the 1st and 5th
metatarsal heads using the Horwell Neurothesiometer (Scientific
Laboratory Supplies, Nottingham, United Kingdom). Reduced
vibration perception was defined by a vibration perception
threshold $25 Volts in either foot [15]. Light touch perception
was evaluated using a 10-g Semmes-Weinstein monofilament
(Huntleigh Diagnostics, Cardiff, United Kingdom) at four sites of
the foot (the plantar and dorsal aspect of 1st and 5th metatarsal
heads) The participant should close his/her eyes when being tested
and then recognize the perception of the pressure at correct site.
Areas of callus were avoided when testing. Loss of perception at
any of the four sites was defined as reduced touch perception.
[16,17]. Pinprick sensation test was performed by using a
disposable pin with just enough pressure to deform the skin on
the dorsal surface of the hallux. Loss of pinprick sensation was
defined as failure to perceive pinprick over either hallux. [17] All
the assessments were conducted by an assessor first and then
confirmed by a second assessor independently.
Participants were instructed to fast and abstain from vigorous
exercise for 12 hours prior to medical examination and blood
draw. Fasting venous blood samples (10 ml) were taken from
antecubital vein by the laboratory staff and sent to the KAUH’s
accredited central laboratory for daily assay. Fasting blood
glucose, HbA1c [18], lipids profile [high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglyceride (TG)] [19],
homocysteine [20], creatinine [21], high sensitivity C-reactive
protein (CRP) [22], serum urea nitrogen, hemoglobin, and
complete blood count were measured using standard methods.
Statistical analyses
The distributions of continuous variables were presented as
median and interquartile range. A comparison of continuous
variables between DPN and non-DPN participants was done by
quantile regression with adjustment for age, sex and nationality
when applicable. All the categorical variables were presented as
number and percentage. For the clinical marker data, there were
some missing values due to laboratory technical failure or
participants’ refusal to provide blood samples. Logistic regression
model adjusted for age, sex and nationality was employed to
compare the distribution of categorical variables between DPN
and non-DPN participants. Less than 10% of clinical marker
measurements were missing except for LDL (10.9%), homocyste-
ine (26.8%) and CRP (11.2%). We therefore used the median
value of each clinical marker to impute the missing values. Logistic
regression model was used to examine the association between
correlates and DPN. The first logistic regression model (model 1)
estimated odds ratio (OR) and its 95% confidence interval (CI) for
each correlate with adjustment for sex, age (continuous) and
nationality (Saudi, non-Saudi). In the model 1, all the continuous
variables were categorized into quartiles. To further explore
significant independent correlates for DPN, we used a backward
selection algorithm beginning with a model including all the
potential correlates listed in Table 1. Sex and age were forced to
be included in the model. A variable was ultimately retained in the
final model if its P value #0.1 to accommodate the selection of
important correlates. Model 2 examined the association between
each selected independent correlates and DPN with adjustment for
other independent correlates. In the sensitivity analysis, we
repeated the same backward selection algorithm but excluded
participants with type 1 diabetes from our analytical population.
All statistical analyses were conducted using SAS 9.2 software
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. Non-DPN case DPN case P
{
(N=441) (N=110)
Sex, male ` 278 (62.9) 68 (61.8) 0.577
Nationality, Saudi 273 (61.8) 60 (54.5) 0.044
Education 0.202
Illiterate 160 (36.2) 53 (48.2)
High school 121 (27.4) 24 (21.8)
University 133 (30.1) 27 (24.5)
Post graduate 28 (6.3) 6 (5.5)
Income level (SR/month) 0.232
,3000 176 (39.8) 54 (49.1)
3000–10000 162 (36.7) 36 (32.7)
.10000 104 (23.5) 20 (18.2)
Obesity 215 (48.6) 62 (56.4) 0.055
Abdominal obesity 266 (60.2) 87 (79.1) ,.001
Smoking status, ever smoker 90 (20.4) 21 (19.1) 0.661
Type of diabetes, type 2 422 (95.7) 102 (92.7) 0.011
Duration of diabetes (years) ,.001
2–5 132 (29.9) 8 (7.3)
5–10 120 (27.1) 11 (10.0)
10–20 135 (30.5) 37 (33.6)
.20 55 (12.4) 54 (49.1)
Hypertension 270 (61.1) 86 (78.2) 0.017
Insulin 134 (30.3) 68 (61.8) ,.001
Oral hypoglycemic 376 (85.1) 76 (69.1) ,.001
Aspirin 250 (56.6) 75 (68.2) 0.675
Plavix 27 (6.1) 14 (12.7) 0.360
Statins 159 (36.0) 54 (49.1) 0.044
Age (years)
1 52.0 (46.0–58.0) 59.5 (50.0–66.0) ,.001
Body mass index (kg/cm
2) 29.7 (26.8–34.1) 30.8 (27.4–36.6) 0.246
Height (cm) 164.3 (157.0–172.0) 164.0 (158.0–172.0) 0.083
Waist circumference (cm) 100 (93–108) 105 (96–115) 0.001
Fasting blood glucose (mmol/L) 9.4 (7.7–12) 9.7 (7.9–13.9) 0.002
HbA1c (%) 9.0 (8.0–10.6) 9.0 (8.0–11.0) 0.147
HDL (mmol/L) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 0.293
LDL (mmol/L) 3.0 (2.5–3.7) 3.0 (2.5–3.7) 0.755
Triglyceride (mmol/L) 1.5 (1.0–2.0) 1.5 (1.1–2.1) 0.184
Homocysteine (ı `mol/L) 7.7 (6.4–8.9) 7.7 (7.7–9.7) 0.164
Creatinine (ı `mol/L) 78.0 (64.0–88.0) 82.0 (75.0–103.0) 0.041
CRP (mg/L) 3.3 (3.2–5.8) 3.4 (3.3–9.5) 0.058
Serum urea nitrogen (mmol/L) 5.0 (4.0–5.9) 5.5 (4.7–7.7) 0.097
Hemoglobin (g/dL) 13.8 (12.8–14.9) 13.6 (12–14.5) 0.093
White blood cell (10
6/L) 7.1 (5.9–8.5) 7.5 (6.4–9.5) 0.041
Platelet (10
9/L) ) 252.5 (219.0–294.0) 252.5 (205.0–285.0) 0.084
Abbreviations: DPN, diabetic peripheral neuropathy; SR, Saudi riyal (currency unit of Saudi Arabia); HbA1c, glycated hemoglobin; HDL, high-density lipoprotein
cholesterol; LDL, low-density lipoprotein cholesterol; CRP, C-reactive protein.
{P-values were calculated from logistic regression models for categorical variables or quantile regression for continuous variables adjusted for age, sex and nationality
when applicable.
`n (%) for all such values
1median (25% percentile – 75% percentile) for all such values
doi:10.1371/journal.pone.0106935.t001
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except the a for backward elimination).
Results
Table 1 shows characteristics of the study population according
to whether DPN was diagnosed or not. Among the 552
participants, 110 were diagnosed as DPN, representing a
prevalence of 19.9% [95% confidence interval (CI), 16.7% –
23.5%]. The mean age of this population was 53.4610.5 years.
Participants with DPN were older, had longer duration of
diabetes, and higher prevalence of abdominal obesity and
hypertension, compared with their counterparts without DPN.
Insulin was more commonly used in participants with DPN, while
oral hypoglycemic and statin were more commonly used in
participants without DPN (Table 1). Participants with DPN had
significantly higher levels of waist circumference, fasting blood
glucose, creatinine and white blood cell (WBC) count when
compared to participants without DPN.
Table 2 shows the associations between the correlates and DPN
after adjusting for age, sex and nationality. Abdominal obesity,
type 1 diabetes, hypertension and insulin use were significantly
associated with higher odds of DPN. A significant and positive
association between duration of diabetes and odds of DPN was
observed (P trend ,0.001). Participants with duration of diabetes
.20 years presented a 12.19-fold odds of DPN (OR, 12.19, 95%
CI, 5.24–28.36) when compared with those with duration of
diabetes of 2–5 years. In oral hypoglycemic users, a significantly
lower odds of DPN was observed. For clinical markers, higher
levels of homocysteine, creatinine, CRP, serum urea nitrogen and
WBC were significantly associated with higher odds of DPN,
whereas a significantly lower odds of DPN was found among
participants with higher hemoglobin level.
By using a logistic regression model with backward variable
selection, the independent correlates were identified (Table 3).
Every 5-year increase of diabetes history was associated with an
OR of 1.91 for DPN (95% CI, 1.53–2.40). Abdominal obesity was
associated with an OR of 2.53 for DPN (95% CI, 1.41–4.55),
while oral hypoglycemic medication use was associated with an
OR of 0.47 for DPN (95% CI, 0.26–0.85). The ORs for DPN
associated with every 1-unit increment in fasting blood glucose,
creatinine, and WBC were 1.05 (95% CI, 0.99–1.12), 1.07 (95%
CI, 0.99–1.14) and 1.08 (95% CI, 1.01–1.16), respectively. In the
sensitivity analysis, the backward variable selection algorithm
identified the set of independent correlates except oral hypogly-
cemic medication use (Table S1).
Discussion
In this large Saudi population, several independent correlates
for DPN, in addition to blood glucose control and diabetes
duration, were identified, including abdominal obesity, plasma
creatinine and WBC levels.
The observed prevalence of DPN was 19.9% (95% CI, 16.7%–
23.5%) in this diabetic population, which was higher than a
worldwide estimate of DPN prevalence among diabetics (8.1% –
12.2%) [23]. In Saudi Arabia, a prevalence of 65.3% has been
previously reported for painful DPN in a nationally representative
diabetic population. [12] In other Middle East countries, the
prevalence rates of painful DPN were 61.3%, 57.5%, 53.9% and
37.1% for Egyptian, Jordanian, Lebanese, and Gulf States
population, respectively. [24] However, DPN cases in these two
studies was ascertained by questionnaire (Douleur Neuropathique
4, DN4) other than objective measurement and the difference
between our estimates and those from the previous studies in
Middle East countries might be explained by discrepancy on
ascertainment tools and definitions of DPN, which has been
noticed by previous study [25]. A study based on a nationally
representative US population with diabetes that also employed
monofilament testing to detect DPN reported a prevalence of
28.5% [25].
Previous studies [3,4,5] and clinical guidelines [1,26] have
indicated aggressive blood glucose control as a standard clinical
practice in the management of DPN. We observed that a lower
level of fasting blood glucose and oral hypoglycemic use was
associated with lower odds of DPN, which emphasizes the role of
intensive glycemic control in DPN prevention and treatment.
However, in our univariable analysis, we found that insulin use,
another glycemic control medication, was associated with a 3.93-
fold odds of DPN. A similar association between insulin use and
DPN has been reported in previous studies [5,6]. In this study
context, insulin use tends to be an indicator for longer duration
and greater severity of diabetes. Consistent with previous findings
[4,5,27,28], our study also observed that a strong association
between longer duration of diabetes and DPN. Additionally, the
significantly higher odds of DPN in type 1 diabetic participants
observed in the univariable analysis could be ascribed to the longer
course of disease in type 1 diabetics. Even though not a modifiable
risk factor, duration of diabetes is of great importance for early
identification and management of DPN. Previous studies have
suggested that elevated level of HbA1c, a maker for long-term
chronic glycemic exposure, strongly predicted risk of DPN
[5,6,27,28,29], although our study did not observe a significant
association between HbA1c and DPN, especially after adjusting
for duration of diabetes.
Our data suggested that abdominal obesity was a significant and
independent correlate for DPN, whereas general obesity (BMI $
30 kg/m
2) was not significant after multivariate adjustment. This
finding is not surprising given that insulin resistance is more
strongly related to abdominal obesity than general obesity [30].
Previous studies have suggested an association between insulin
resistance with impaired autonomic function and occurrence of
DPN [31]. Existing evidence regarding the association between
abdominal obesity and DPN was sparse and inconsistent. Some
previous studies addressed the association between abdominal
obesity and peripheral neuropathy (PN) in study populations
including both diabetics and non-diabetics, and reported an
positive association between waist circumference and PN [32,33].
In a community-based Australian population, no significant
association between waist circumference and DPN was observed
in either newly diagnosed or prevalent diabetic populations [34].
Considering aggressive treatment of hypertension and dyslipi-
demia has become standard clinical practices in the management
of diabetic nephropathy and retinopathy, emerging evidence has
suggested that hypertension and dyslipidemia could also be new
targets for both DPN prevention and treatment [5,35,36]. Our
study found a significant association between statin use and DPN,
but non-significant association between lipid profile and DPN.
These findings could be attributed to a high prevalence of statin
use in this population (38.5%). Statin was likely to be a surrogate
for dyslipidemia in this population. In this study, hypertensive
participants were more prone to have DPN when comparing to
normotensive participants in the univariable analysis, which was
consistent with previous findings [5,6,37]. However, this associa-
tion disappeared in the multivariable analysis.
This current analysis observed an elevated level of CRP, a
circulating maker of inflammation, among DPN cases. Our
finding is consistent with a previous report from Herder et al., in
which a high level of CRP was found to be associated with diabetic
Diabetic Peripheral Neuropathy in Saudi Arabia
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{
Cases (%) Odds ratio (95% CI) P
`
Education 0.770
Illiterate 53 (24.9) Reference
High school 24 (16.6) 0.97 (0.54–1.76)
University 27 (16.9) 0.90 (0.51–1.59)
Post graduate 6 (17.6) 0.97 (0.36–2.63)
Income level (SR/month) 0.702
,3000 54 (23.5) Reference
3000–10000 36 (18.2) 0.97 (0.56–1.68)
.10000 20 (16.1) 0.86 (0.43–1.73)
Obesity 62 (22.4) 1.57 (1.00–2.48) 0.052
Abdominal obesity 87 (24.6) 2.65 (1.55–4.56) ,.001
Smoking, ever-smoker vs. never-smoker 21 (18.9) 1.17 (0.66–2.08) 0.602
Type of diabetes, type 1 vs. type 2 102 (19.5) 4.08 (1.58–10.57) 0.004
Duration of diabetes (years) ,.001
2–5 8 (5.7) Reference
5–10 11 (8.4) 1.48 (0.57–3.83)
10–20 37 (21.5) 3.80 (1.68–8.60)
.20 54 (49.5) 12.19 (5.24–28.36)
Hypertensive vs. normotensive 86 (24.2) 1.79 (1.07–2.99) 0.025
Insulin, user vs. non-user 68 (33.7) 3.93 (2.48–6.22) ,.001
Oral hypoglycemic, user vs. non-user 76 (16.8) 0.31 (0.19–0.53) ,.001
Aspirin, user vs. non-user 75 (23.1) 1.25 (0.78–1.99) 0.350
Plavix, user vs. non-user 14 (34.1) 1.78 (0.87–3.64) 0.114
Statins, user vs. non-user 54 (25.4) 1.51 (0.97–2.34) 0.067
Height (cm) 0.113
,157.5 27 (19.6) Reference
157.5–164.0 32 (22.5) 1.39 (0.72–2.69)
164.0–172.0 22 (16.7) 1.28 (0.55–2.95)
$172.0 29 (20.7) 2.10 (0.88–5.03)
Fasting blood glucose (mmol/L) 0.053
,7.7 26 (19.1) Reference
7.7–9.4 27 (16.8) 0.91 (0.49–1.68)
9.4–12.5 24 (20.5) 1.17 (0.61–2.23)
$12.5 33 (23.9) 1.64 (0.90–3.02)
HbA1c (%) 0.338
,8.0 27 (21.1) Reference
8.0–9.0 16 (15.5) 0.65 (0.32–1.32)
9.0–10.6 37 (20.1) 0.99 (0.55–1.78)
$10.6 30 (21.9) 1.20 (0.65–2.23)
HDL (mmol/L) 0.881
,1.0 30 (21.7) Reference
1.0–1.1 17 (15.2) 0.63 (0.32–1.24)
1.1–1.3 35 (21.3) 0.98 (0.55–1.74)
$1.3 28 (20.3) 0.94 (0.51–1.76)
LDL (mmol/L) 0.717
,2.5 28 (20.4) Reference
2.5–3.0 27 (25.2) 1.56 (0.83–2.94)
3.0–3.7 28 (16.5) 1.09 (0.59–2.02)
$3.7 27 (19.6) 1.21 (0.65–2.24)
Triglyceride (mmol/L) 0.138
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increased CRP level has also been observed among diabetic foot
ulcer patients [39]. However, after multivariable adjustment CRP
was not an independent correlate for DPN in the study, while
Herder et al. found an independent and persistent association
between CRP and polyneuropathy even after multivariable
adjustment. Another biomarker of inflammation, WBC count,
was independently and positively associated with the presence of
DPN in our analysis. To our knowledge, our analysis is the first
epidemiological study that demonstrated this independent associ-
ation. A recent breakthrough of pathological mechanism of DPN
was the finding of inflammatory infiltrates around epineurial and
perineurial blood vessels from biopsy specimen, suggesting
inflammatory process was responsible for occurrence of DPN in
Table 2. Cont.
Cases (%) Odds ratio (95% CI) P
`
,1.0 25 (18) Reference
1.0–1.5 28 (17.9) 1.02 (0.55–1.89)
1.5–2.0 25 (21.2) 1.18 (0.62–2.25)
$2.0 32 (23) 1.51 (0.82–2.77)
Homocysteine (ı `mol/L) 0.087
,6.6 14 (9.9) Reference
6.6–7.7 9 (14.8) 1.44 (0.58–3.62)
7.7–9.0 53 (24.9) 2.38 (1.24–4.58)
$9.0 34 (24.8) 2.15 (1.06–4.34)
Creatinine (ı `mol/L) ,.001
,66.0 15 (10.5) Reference
66.0–78.0 29 (18.4) 2.30 (1.14–4.65)
78.0–90.0 23 (20.9) 2.52 (1.17–5.41)
$90.0 43 (30.5) 3.69 (1.76–7.75)
CRP (mg/L) ,.001
,3.2 18 (13.0) Reference
3.2–3.3 23 (20.7) 1.74 (0.86–3.55)
3.3–6.8 29 (17.6) 1.73 (0.88–3.40)
$6.8 40 (29.0) 3.55 (1.81–6.98)
Serum urea nitrogen (mmol/L) 0.002
,4.1 15 (10.9) Reference
4.1–5.0 21 (18.6) 1.69 (0.81–3.54)
5.0–6.1 29 (17.6) 1.75 (0.87–3.50)
$6.1 45 (33.1) 2.92 (1.47–5.79)
Hemoglobin (g/dL) 0.011
,12.7 39 (28.5) Reference
12.7–13.8 28 (17.4) 0.51 (0.27–0.96)
13.8–14.8 28 (23.7) 0.73 (0.37–1.43)
$14.8 15 (11.0) 0.32 (0.15–0.72)
White blood cell (10
6/L) 0.003
,5.9 19 (13.6) Reference
5.9–7.1 22 (19.6) 1.51 (0.76–3.02)
7.1–8.7 28 (17.0) 1.35 (0.70–2.58)
$8.7 41 (30.4) 2.58 (1.37–4.85)
Platelet (10
9/L) ) 0.315
,217.0 33 (24.1) Reference
217.0–252.5 21 (17.2) 0.71 (0.37–1.33)
252.5–290.5 32 (20.6) 0.92 (0.51–1.64)
$290.5 24 (17.4) 0.69 (0.36–1.31)
Abbreviations: SR, Saudi riyal (currency unit of Saudi Arabia); HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein
cholesterol; CRP, C-reactive protein.
{Logistic regression model adjusted for sex, age (continuous) and nationality (Saudi, non-Saudi).
`For ordinal variables, P-value was estimated from the linear trend test.
doi:10.1371/journal.pone.0106935.t002
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demonstrated that accumulation of advanced glycation end
products (AGEs), caused by long-term exposure to hyperglycemia,
correlated with the severity of peripheral and autonomic nerve
abnormalities in diabetes even before being clinically manifest; the
AGE–RAGE (receptor for AGE) interaction was a propagating
factor for chronic inflammation [40]. As clinical markers for renal
function, creatinine and serum urea nitrogen were related to DPN
in this study. In addition, creatinine was identified as an
independent correlate for DPN. This finding is consistent with
previous studies [41,42]. Nephropathy, as another common
diabetes complication, is often concomitant with DPN, accounting
for the elevated levels of these two clinical markers of renal
function [37].
We also observed a strong positive association between elevated
level of homocysteine, an indicator of oxidative stress, and DPN in
the univariable analysis, but this association disappeared in our
multivariable analysis. A increasing body of evidence has suggested
the important role of oxidative stress in the pathogenesis of
diabetic neuropathy in animal models [23]. In addition, a clinical
trial in a German population found that a-lipoic acid, a powerful
antioxidant, had positive effect on alleviating neuropathic symp-
toms, also providing supporting evidence for the relationship
between oxidative stress and DPN [43]. It is of interest that a
negative association between hemoglobin level and DPN was
found in this study. We regarded hemoglobin level as an indicator
for severity of diabetes in this context, since previous study has
already found anemia was a common accompaniment to diabetes,
as well as a negative association between severity of diabetes and
hemoglobin level [44]. However, the possibility that hemoglobin
may be an indicator for hypoxic damage cannot be ruled out, since
that microvascular damage caused by long-term exposure to
hyperglycemia may lead to diminished blood flow to nerve tissues
vulnerable to hypoxic damage, and thereby to the development of
neuropathy [45].
To our knowledge, this is the first study on correlates of DPN in
a Saudi population. The strengths of this study include a large
sample size and a detailed and objective assessment of DPN.
Combining the validated tests for superficial and deep sensations
and neurological symptoms, the diagnosis procedure had enough
sensitivity in detecting DPN [46,47]. In addition, comprehensive
measures of clinical and biochemical markers were assessed.
However, several limitations of this study warrant attentions. First,
the cross-sectional nature of this study design limits the inference
of causal relationship between correlates and DPN. Therefore, our
findings need to be confirmed in prospective studies. Secondly,
because we used advertisement to recruit participants, eligible
participants with severe potential risk factors might not be able or
willing to participate in this study. Thus, findings from this study
may not be generalizable to other populations. Thirdly, since the
diagnosis of DPN was only based on a combination of decreased
sensation and neuropathic sensory symptoms, without nerve
conduction test[26], possible misclassification of DPN diagnosis
cannot be ruled out. However, previous study has found a
relatively high sensitivity of the criteria employed by the current
study (.87%) [1]. Therefore, the misclassification is likely to be
small. Lastly, even though we imputed missing values for clinical
markers by their median values, potential selection bias introduced
by imbalance between participants with and without missing
values could not be ruled out. However, the characteristics of
participants with and without missing values were generally
balanced (data not shown), indicating that the likelihood of
selection bias was relatively small.
In conclusion, a higher prevalence of DPN was observed in this
Saudi population with diabetes, compared to the worldwide
average estimate. In line with previous findings, diabetes duration
and glycemic control were strongly associated with DPN. Other
correlates, including abdominal obesity and two relatively novel
clinical markers (creatinine and white blood cell count) were also
identified, which may contribute to the risk prediction of DPN.
Furthermore, targeting patients with high risk of DPN in foot
education programs may have important clinical implication in
preventing foot ulceration and subsequent lower-extremity ampu-
tation, especially in countries, like Saudi Arabia, with high disease
burden of diabetes. To further address prediction of DPN risks in
Saudi populations with diabetes, prospective cohort studies are still
warranted.
Supporting Information
Table S1 Backward multivariate logistic regression of
risk factors associated with diabetic peripheral neurop-
athy among participants with type 2 diabetes.
(DOCX)
Table 3. Backward multivariate logistic regression of risk factors associated with diabetic peripheral neuropathy.
{
Odds ratio 95% CI P
`
Sex, male vs. female 0.76 (0.44–1.29) 0.305
Age (years), every 1-year increase 1.04 (1.01–1.06) 0.008
Nationality, Saudi vs. non-Saudi 0.57 (0.35–0.94) 0.027
Abdominal obesity, case vs. non-case 2.53 (1.41–4.55) 0.002
Oral hypoglycemic, user vs. non-user 0.47 (0.26–0.85) 0.012
Duration of diabetes, every 5-year increase 1.91 (1.53–2.40) ,.001
Fasting blood glucose, every 1-mmol/L increase 1.05 (0.99–1.12) 0.082
Creatinine, every 10-ı `mol/L increase 1.07 (0.99–1.14) 0.076
White blood cell, every 10
6/L increase 1.08 (1.01–1.16) 0.021
{Logistic regression model adjusted for sex, age (continuous), nationality (Saudi Arabia, non-Saudi Arabia), abdominal obesity (case, non-case), Oral hypoglycemic (user,
non-user), duration of DM (every 5 years), fasting blood glucose (every 1 mmol/L), creatinine (every 10 ı `mol/L), and White blood cell (every 10
6/L).
`For ordinal variables, P-value was estimated from the linear trend test.
doi:10.1371/journal.pone.0106935.t003
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